In May 2023, Librela, a high-profile product, was approved through FDA for the control of pain associated with dog arthritis (OA), the first single clone antibody drug (mAb) approved by FDA for dog disease treatment.
In June 2023, the high-profile production of Oklahidini chews was approved through the FDA, which is used to control dogs ' aching associated with allergies and ad hoc dermatitis. The product was the first chewing product in the United States to control dog allergies and inflammation.
Currently, both products are officially listed on the United States market and can be purchased by prescriptions issued by United States veterinary doctors.
“As recognized leaders in the field of canine health care, dedicated to continuing to explore opportunities to advance dog treatment,” said Ester Banque, Executive Vice President and Managing Director of United States Operations. “Librela offers an innovative choice of treatment for veterinary treatment that can improve the dependence and quality of life of pets. OA pain is a common disease for many dogs, and we look forward to working with veterinarians to have a positive impact on the health and well-being of dogs and to further strengthen the bond between pet owners and dogs.
Bedinvetmab injection is a single cloned antibody therapy administered monthly by veterinary professionals, with a body weight range and a target minimum dose of 0.5 mg/ kg.
Octatini chewing is an oral drug with a guaranteed specification of 250 and a dose of 0.4 to 0.6 mg Octatini/kg) twice a day for 14 days and then once a day for maintenance treatment. Three.
“In addressing the common health problems of dogs, our approach is to understand the unmet needs of clients and to apply our scientific expertise to the development of the best solutions.” Dr. Robert J. Polzer, Managing Director and Research and Development, stated.
“We are committed to exploring new treatments and formulations to reflect the real needs of pet owners. Innovative products such as Librela and Apoquel Chewable allow veterinarians to provide personalized treatment to the dogs they care for, which can lead to better treatment outcomes for these animals.